Sou Hu Cai Jing·2025-04-18 00:38Market Performance - On April 18, 2025, A-shares showed mixed results with the Shanghai Composite Index up 0.13% at 3,280.34 points, while the Shenzhen Component Index fell 0.16% to 9,759.05 points. The total trading volume in the Shanghai and Shenzhen markets was 999.5 billion yuan, a decrease of 112.4 billion yuan from the previous trading day [1] - Hong Kong stocks rebounded strongly, with the Hang Seng Index rising 1.61% or 338.16 points to 21,395.14 points, and a total trading volume of 192.41 billion HKD [1] - In the U.S., the Dow Jones Index fell 1.33% to 39,142.23 points, while the S&P 500 Index rose 0.13% to 5,282.70 points, and the Nasdaq Index decreased by 0.13% to 16,286.45 points [1] Financial Industry Regulations - On April 17, 2025, six departments, including the central bank, issued guidelines to promote and regulate the cross-border flow of financial data, aiming for more efficient and standardized data movement between domestic and foreign financial institutions [3] - The guidelines specify the circumstances under which data can be exported and provide a list of data items that can flow across borders, emphasizing the need for financial institutions to implement necessary data security measures [3] E-commerce Regulation - On April 17, 2025, the State Administration for Market Regulation held a meeting to address the rapid development of the live-streaming e-commerce sector, which is seen as a vital part of the platform economy [4] - The meeting highlighted the need for businesses in this sector to operate legally and ethically, as issues like counterfeit products and false marketing persist [5] - The administration plans to enhance regulatory enforcement and establish a long-term regulatory mechanism through the introduction of the "Live-streaming E-commerce Supervision Management Measures" [5] Automotive Industry Concerns - On April 17, 2025, the Ministry of Public Security's Road Traffic Safety Research Center warned about the dangers of misusing advanced driver-assistance systems, which has led to traffic accidents due to drivers misunderstanding the capabilities of these systems [6] - The article emphasized that misleading advertising regarding these systems could lead to severe penalties, including fines and potential imprisonment for responsible parties if serious accidents occur [6] Pharmaceutical Industry Developments - On April 17, 2025, Eli Lilly announced positive results from its Phase 3 trial for Orforglipron, the first oral GLP-1 receptor agonist, which showed safety and efficacy in adults with type 2 diabetes inadequately controlled by diet and exercise [6] - The company expressed confidence in its ability to launch Orforglipron globally without supply constraints if approved [6]